PanXome News

PanXome receives GA Bio Innovation Award
Feb 16, 2018- Georgia Bio recognized PanXome last night in the annual awards banquet by awarding PanXome the Innovation Award. Jack Miller, CEO, and Jeff Skolnick, CSO, accepted the award on behalf of the company.  


PanXome picked to present at RAISE Forum
Oct 24, 2017- The RAISE Forum introduces the best companies to interested and active investors in a concise and efficient day of formal presentations and informal consultations. RAISE is creating local funding for in-revenue companies that are in the healthcare industry. PanXome was selected by RAISE to present to the investor group at the forum on November 10th.

Industry News

"A Dynamic Map For Learning, Communicating, Navigating and Improving Therapeutic Development"
March 10, 2018- Drug discovery is a long and intricate process that is often mistaken for a unidirectional "pipeline", when in reality it is a diverse web that flows in multiple directions. John Wagner of The Forum on Drug Discovery, Development, and Translation of the US National Academies of Sciences, Engineering, and Medicine discusses the drug development processes and provides a realistic flow map of how drug discovery actually works. Check out the graphic below. ... Read more.


"DeepMind's Superpowerful AI Sets Its Sights on Drug Discovery"
Oct 18, 2017
- Jeremy Kahn of Bloomberg Technology discusses the company DeepMind's new AI, AlphaGo Zero, that will predict protein folding. While supercomputers have previously been applied to protein folding, the results have not been spectacular. Leaps forward in artificial intelligence have mostly come from bigger and better data sets and more powerful computers. “It is the novel algorithms that really matter. It is actually the algorithmic advances that lead to more progress than either compute power or data” says David Silver, a researcher on the project. ... Read more. 

"The Cost Of Developing Drugs Is Insane. The Paper That Says Otherwise Is Insanely Bad."
Oct 16, 2017- Matthew Herper of Forbes reviews a paper published in JAMA internal medicine last month claiming that the cost of bringing a medicine from invention to pharmacy shelves is only $648 million. Most other estimates range from $2-7 billion. According to Herper, the $648 million estimate doesn't stand under scrutiny and has "survivorship bias." Herper summarizes this underestimate by saying "Quibble about the details, but pharma companies do really spend billions for every drug that reaches the market. So, then, the elephant in the room: Do high R&D costs justify high drug prices? Of course not. Not by themselves. The medicines have to be worth the money, too." ... Read more.

"Artificial Intelligence In Drug Discovery: A Bubble Or A Revolutionary Transformation?"
Aug 3, 2017- Andrii Buvailo of the Forbes Technology Council comments on AI and its use in life sciences- specifically drug discovery. Many media sources and drug discovery companies are hyping up how artificial intelligence will be the future of healthcare but AI needs to be taken with a grain of salt. As Buvailo says, " is important to realize that while AI-based data analytics can bring innovation at every stage of drug discovery and during the development process, this data will not magically serve as a substitute for chemical synthesis, laboratory experiments, trials, regulatory approvals and production stages." However, AI can significantly "optimize and speed up R&D efforts, minimize the time and cost of early drug discovery, and help anticipate possible toxicity risks or side effects at late-stage trials to hopefully avoid tragic incidents in human trials. It can help incorporate knowledge derived from genomics and other biology disciplines into drug discovery considerations to come up with revolutionary ideas for drugs and therapies." The computing power of today provides artificial intelligence with the opportunity for major industry disruptions in the next couple of years. Buvailo summarizes the future of AI by saying "The necessity to start embracing AI technologies and revamping human resource strategies to create data science-driven interdisciplinary teams has become a matter of the future business sustainability for biopharma organizations." ... Read more.

"Drug Industry Bets Big On Precision Medicine: Five Trends Shaping Care Delivery."
Mar 8, 2017- Forbes contributor Reenita Das discusses personalized precision medicine and the death of "one size fits many" care models. Das states the five key trends shaping the transformation to precision medicine- (1) Unreasonable cost of trial-and-error medicine (2) Scientific and technological advances in the genomics field mean that cost and time are no longer a barrier for precision medicine (3) The precision medicine focus now goes beyond oncology (4) Precision medicine will harness healthcare big data (5) Precision medicine will boost the healthcare consumerism moment ... Read more.

"Artificial Intelligence Can Now Predict Heart Failure and That May Save Lives."
Jan 17, 2017- Dyllan Furness of Digital Trends reviews a new paper published in Radiology, where an AI system has accurately predicted when patients with heart conditions will die. The AI was assigned 256 patients with pulmonary hypertension and the AI predicted with 80 percent accuracy which patients would die in the next year. The average doctor’s accuracy is about 60 percent. AI has also been used to diagnose eye disease using Google's machine learning software and breast cancer with 92% accuracy. ... Read more.

Meet Us

PanXome is attending the following upcoming conferences:

BioEurope 2018
Amsterdam the Netherlands, March 12-14 2018

BioIT World 2018
Boston USA, May 15-17 2018

Boston USA, June 4-7 2018